

# Mortality of 5-Year Time-Averaged Low Serum Calcium <8.5 mg/dL in Subgroups of Hemodialysis (HD) Patients

Jessica E Miller<sup>1,2</sup>; Csaba P Kovcsy<sup>3</sup>; David Van Wyck<sup>4</sup>; Allen R. Nissenson<sup>4</sup>; Joel D Kopple<sup>1</sup>; and Kamyar Kalantar-Zadeh<sup>1,2</sup>

(1) Harold Simmons Center for Kidney Disease Research and Epidemiology, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, and David Geffen School of Medicine at UCLA, Torrance and Los Angeles, CA; (2) Dept of Epidemiology, UCLA School of Public Health, Los Angeles, CA; (3) Salem VA Medical Center, Salem, VA; and (4) DaVita, Inc, El Segundo, CA



## Background



- Several epidemiologic studies have examined the mortality-predictability of "baseline" serum calcium in maintenance hemodialysis (MHD) patients, ignoring subsequent serum calcium values over time
- However, the time-averaged values, by accounting for all monthly measured serum calcium levels up to the time of death or censorship, may more appropriately reflect the cumulative effect of serum calcium over time on survival

## Methods

- In a large and contemporary cohort of 151,555 MHD patients who underwent dialysis treatment for at least 3 months in all legacy DaVita dialysis clinic between July 2001 and June 2006, all monthly measured (and albumin adjusted) serum calcium levels were averaged into one single value per patient during the entire follow-up time, i.e., up to 5 years
- Analytical Method: Cox survival modeling
- The death hazard ratio (and 95% CI) of the serum calcium were calculated at 3 levels of multivariate adjustments:
  - Unadjusted
  - Case-mix adjusted: Demographics and comorbidity (age, gender, race/ethnicity, diabetes, vintage, insurance, marital status) and dialysis dose (Kt/V)
  - Malnutrition-inflammation complex syndrome (MICS) adjusted: Protein intake (nPNA or nPCR), administered EPO dose, serum albumin, creatinine, phosphorus, ferritin, TIBC, hemoglobin, WBC, and lymphocyte%, paricalcitol dose

## Results

- In a logistic regression model case-mix-adjusted for age, gender, race, comorbidity, vintage, and dialysis dose, the odds ratio of achieving the highest quartile in ESA responsiveness (versus the lowest quartile) increased progressively with increasing serum calcium level
- For each 1 mg/dL increase in 3-month averaged serum calcium, odds ratio increased by 1.27 (95% CI: 1.22-1.32, p<0.001). Hypocalcemia (Ca <8.4 mg/dL) was associated with an adjusted odds ratio of 0.61 (95% CI: 0.55-0.68, p<0.001); see Figure 1 (below)



## Conclusions

In 151,555 prevalent MHD patients who were followed for up to 5 years, cumulative hypercalcemia (>10.5 mg/dL) was associated with 2 to 2.5 times increased death risk and cumulative hypocalcemia (<8.5 mg/dL) with 25% to 50% higher death risk.

## Acknowledgements

**Correspondence:**  
Kamyar Kalantar-Zadeh, MD, MPH, PhD  
Harold Simmons Center for Kidney Disease Research & Epidemiology,  
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center  
1124 W. Carson St., C-1 Annex  
Torrance, CA 90502-2064  
Tel: (310) 222-3891  
Cell: (310) 686-7908  
Fax: (310) 782-1637  
Email Address: [kaikal@ucla.edu](mailto:kaikal@ucla.edu)

**Funding Source:** Funding Source: Supported by an investigator-initiated research grant from Abbott, a research grant from DaVita Clinical Research (DCKR), and philanthropist Mr. Harold C. Simmons. KKZ has been supported by American Heart Association (AHA) grant 065576Y and NIH/NIIDK grants R01 DK078106 and R21 DK078012. DCKR provided the clinical data for this research project and is committed to advancing the knowledge and practice of kidney care.  
**Relevant Conflict of Interest:** KKZ has received grants and/or honoraria from Abbott (the manufacturer of Zenplur™), Amgen (manufacturer of senpar™), Genzyme (manufacturer of Sevelamer™ and Hecoral™) and/or Shire (manufacturer of Forxiga™).